New Actos suits go straight to MDL
  • Fri, 06/29/2012 - 3:21pm

New lawsuits against Takeda Pharmaceuticals’ Type 2 diabetes drug Actos can move straight to the Multidistrict Litigation case thanks to an alteration in court procedures, according to patient advocacy group Actos Resource Center.

U.S. District Judge Rebecca Doherty recently signed a direct-filing order so patients suffering as a result of Actos use will no longer have to wait for their local court to transfer their case to the Multidistrict Litigation (MDL) case. MDL cases enable injured parties to consolidate their cases to share information such as evidence but still remain individual lawsuits and receive separate awards. The Actos Resource Center hopes this order will ease the litigation process and lead to faster closure those who were injured while taking the drug.

The patient advocacy group strives to aid patients who have suffered from Actos-induced bladder cancer, heart attacks, or liver damage in exploring possible legal options. According to a Bloomberg report, Takeda Pharmaceuticals could face up to 10,000 lawsuits as a result of negligent manufacturing and marketing of the popular type 2 diabetes medication.

Actos (pioglitazone) is a thiazolidinedione, which increases insulin sensitivity in patients with type 2 diabetes. According to WebMD, the disease occurs when the body cannot produce enough insulin or cannot process the insulin produced.

If you have recently suffered from bladder cancer, a heart attack, or liver damage as a result of taking Actos, you may be entitled to compensation. Please contact an Actos attorney for more information.


About the Contributor

Jessica Davids
I report on FDA developments and new pharmaceutical launches, risks, and safety concerns.

Related Posts